Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Avelox, Vigamox, Moxiflox
Moxifloxacin is a fourth-generation fluoroquinolone antibiotic used to treat a variety of bacterial infections. It works by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication and repair. Moxifloxacin exhibits broad-spectrum activity against both Gram-positive and Gram-negative bacteria, including some atypical pathogens.
Used to treat bacterial infections such as pneumonia, bronchitis, sinusitis, skin infections, and abdominal infections.
WARNING: TENDINITIS AND TENDON RUPTURE, PERIPHERAL NEUROPATHY, CENTRAL NERVOUS SYSTEM EFFECTS, EXACERBATION OF MYASTHENIA GRAVIS Fluoroquinolones, including moxifloxacin, are associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is further increased in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. Discontinue moxifloxacin at the first sign of tendon pain, swelling, or inflammation. Avoid use of moxifloxacin in patients with a history of fluoroquinolone-associated tendinitis or tendon rupture. Fluoroquinolones may cause peripheral neuropathy. Inform patients of this potential side effect and discontinue moxifloxacin at the first sign or symptom of peripheral neuropathy. Central nervous system effects (including, but not limited to, dizziness, lightheadedness, confusion, hallucinations, paranoia, depression, nightmares, anxiety, agitation, and tremors) have been reported with moxifloxacin and other fluoroquinolones. Discontinue moxifloxacin if a patient experiences any of these central nervous system effects. Fluoroquinolones may exacerbate muscle weakness in persons with myasthenia gravis. Avoid moxifloxacin in patients with known history of myasthenia gravis.
Outcome:
Increased risk of bleeding
Mechanism:
Moxifloxacin can enhance the anticoagulant effects of warfarin.
Outcome:
Reduced moxifloxacin absorption
Mechanism:
Chelation and reduced bioavailability.
Outcome:
May slightly delay absorption
Mechanism:
Delayed gastric emptying.
Most likely new formulation: Extended-release oral formulation for improved patient compliance (Year: 2026, 70% confidence)
Based on current usage trends and emerging resistance patterns, moxifloxacin is predicted to maintain its clinical utility for the treatment of specific bacterial infections, with an 80% likelihood of remaining a first-line therapy for community-acquired pneumonia over the next 5 years.
Antibiotic, Fluoroquinolone
Fluoroquinolone